| iloperidone / Generic mfg. |
NCT05648591: Safety and Tolerability of Open-Labeled Iloperidone in Adolescents |
|
|
| Recruiting | 4 | 100 | US | Iloperidone, VYV-683, FANAPT | Vanda Pharmaceuticals | Schizophrenia, Bipolar I Disorder | 09/24 | 09/24 | | |
NCT04819776 / 2020-000405-83: Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder |
|
|
| Completed | 3 | 417 | Europe, US | Iloperidone, FANAPT®, VYV-683, Iloperidone Placebo | Vanda Pharmaceuticals, Vanda Pharmaceuticals Inc. | Bipolar I Disorder | 09/22 | 08/23 | | |
2020-000405-83: A clinical study to evaluate iloperidone in the treatment of patients with acute manic episodes associated with Bipolar I Disorder Badanie kliniczne oceniające stosowanie iloperidonu w leczeniu pacjentów z ostrymi epizodami manii związanymi z chorobą dwubiegunową typu I |
|
|
| Not yet recruiting | 3 | 400 | Europe, RoW | Iloperidone, VYV-683, Capsule, Tablet | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Acute manic episodes associated with Bipolar I Disorder Ostre epizody manii związane z chorobą dwubiegunową typu I, Bipolar I Disorder Choroba dwubiegunowa typu I, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT05344365: A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis |
|
|
| Withdrawn | 2 | 24 | US | Iloperidone, VYV-683, FANAPT | Vanda Pharmaceuticals | Parkinson Disease Psychosis | 11/23 | 11/23 | | |
NCT04712734: A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia |
|
|
| Completed | 1 | 42 | US | Iloperidone, VYV-683 | Vanda Pharmaceuticals | Schizophrenia | 08/22 | 08/22 | | |
NCT06494397: Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions |
|
|
| Not yet recruiting | 1 | 24 | US | VHX-896 and iloperidone, Iloperidone and VHX-896 | Vanda Pharmaceuticals | Schizophrenia, Bipolar I Disorder | 09/24 | 09/24 | | |
